Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Other Non-Current Liabilities: 2015-2025

Historic Other Non-Current Liabilities for Cartesian Therapeutics (RNAC) over the last 8 years, with Sep 2025 value amounting to $848,000.

  • Cartesian Therapeutics' Other Non-Current Liabilities fell 76.39% to $848,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $848,000, marking a year-over-year decrease of 76.39%. This contributed to the annual value of $3.8 million for FY2024, which is 40.01% down from last year.
  • Per Cartesian Therapeutics' latest filing, its Other Non-Current Liabilities stood at $848,000 for Q3 2025, which was down 37.83% from $1.4 million recorded in Q2 2025.
  • Cartesian Therapeutics' Other Non-Current Liabilities' 5-year high stood at $45.5 million during Q1 2021, with a 5-year trough of $848,000 in Q3 2025.
  • Over the past 3 years, Cartesian Therapeutics' median Other Non-Current Liabilities value was $5.4 million (recorded in 2024), while the average stood at $7.8 million.
  • As far as peak fluctuations go, Cartesian Therapeutics' Other Non-Current Liabilities surged by 236.12% in 2023, and later tumbled by 85.27% in 2025.
  • Cartesian Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $25.4 million in 2021, then decreased by 24.71% to $19.1 million in 2022, then slumped by 66.59% to $6.4 million in 2023, then slumped by 40.01% to $3.8 million in 2024, then crashed by 76.39% to $848,000 in 2025.
  • Its Other Non-Current Liabilities stands at $848,000 for Q3 2025, versus $1.4 million for Q2 2025 and $2.0 million for Q1 2025.